Heme oxygenase-1/carbon monoxide system and embryonic stem cell differentiation and maturation into cardiomyocytes by Suliman, Hagir B. et al.
ORIGINAL RESEARCH COMMUNICATION
Heme Oxygenase-1/Carbon Monoxide System
and Embryonic Stem Cell Differentiation
and Maturation into Cardiomyocytes
Hagir B. Suliman,1–3 Fabio Zobi,4 and Claude A. Piantadosi1–3
Abstract
Aims: The differentiation of embryonic stem (ES) cells into energetically efficient cardiomyocytes contributes
to functional cardiac repair and is envisioned to ameliorate progressive degenerative cardiac diseases. Advanced
cell maturation strategies are therefore needed to create abundant mature cardiomyocytes. In this study, we
tested whether the redox-sensitive heme oxygenase-1/carbon monoxide (HO-1/CO) system, operating through
mitochondrial biogenesis, acts as a mechanism for ES cell differentiation and cardiomyocyte maturation.
Results: Manipulation of HO-1/CO to enhance mitochondrial biogenesis demonstrates a direct pathway to ES
cell differentiation and maturation into beating cardiomyocytes that express adult structural markers. Targeted
HO-1/CO interventions up- and downregulate specific cardiogenic transcription factors, transcription factor
Gata4, homeobox protein Nkx-2.5, heart- and neural crest derivatives-expressed protein 1, and MEF2C. HO-1/
CO overexpression increases cardiac gene expression for myosin regulatory light chain 2, atrial isoform,
MLC2v, ANP, MHC-b, and sarcomere a-actinin and the major mitochondrial fusion regulators, mitofusin 2 and
MICOS complex subunit Mic60. This promotes structural mitochondrial network expansion and maturation,
thereby supporting energy provision for beating embryoid bodies. These effects are prevented by silencing
HO-1 and by mitochondrial reactive oxygen species scavenging, while disruption of mitochondrial biogenesis
and mitochondrial DNA depletion by loss of mitochondrial transcription factor A compromise infrastructure.
This leads to failure of cardiomyocyte differentiation and maturation and contractile dysfunction. Innovation:
The capacity to augment cardiomyogenesis via a defined mitochondrial pathway has unique therapeutic po-
tential for targeting ES cell maturation in cardiac disease. Conclusion: Our findings establish the HO-1/CO
system and redox regulation of mitochondrial biogenesis as essential factors in ES cell differentiation as well as
in the subsequent maturation of these cells into functional cardiac cells. Antioxid. Redox Signal. 24, 345–360.
Introduction
Cell therapy holds unique promise in cardiovascularmedicine for the prevention and remediation of diseases
that destroy cardiomyocytes and lead to cardiomyopathies
and congestive heart failure (31, 34, 52). The adult cardio-
myocyte survives energetically through oxidative phosphory-
lation (24), and mitochondrial damage impairs cardiomyocyte
survival and cardiac performance. An optimal complement of
mitochondria is maintained by nuclear programming that is
responsible for coordination of nuclear and mitochondrial-
encoded mitochondrial genes. For example, the protein sub-
units of the mitochondrial electron transport complex (ETC)
are encoded by both genomes (43).Moreover, nuclear-encoded
transcriptional activator proteins such as the nuclear respiratory
factors (NRFs) and peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1a), mitochondrial tran-
scription factor A (Tfam), and DNA polymerase subunit
gamma-1 (Polc) indirectly and directly regulate mitochondrial
DNA (mtDNA) replication and transcription (6, 16, 20).
The embryonic deletion of Polg or Tfam in mice causes
mtDNA depletion and loss of mitochondrial function, leading
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to energy failure and death by days E8.5 (15) and E10.5 (20),
respectively, in part because the energy needs of differenti-
ated cells greatly exceed those of stem cells and must be met
by adjustments in mitochondrial volume and phenotype (9).
Well-differentiated cells exhibit high mtDNA copy number,
distinctive mitochondrial morphology, and well-defined mi-
tochondrial localization (8). Embryonic stem (ES) cells
generally depend on glycolysis, and display low mtDNA
copy number and low mitochondrial density (39, 46, 51).
During differentiation of ES cells, there are striking in-
creases in mtDNA replication and nuclear- and mtDNA-
encoded mitochondrial gene expression (22, 55) followed by
mitochondrial proliferation through the activation of mito-
chondrial biogenesis (46). The implication is that mito-
chondria are necessary for aerobic maturation and possibly
for terminal differentiation of mesenchymal stem cells (8),
cardiac mesangioblasts (41), and ES cells (27). Cardiac dif-
ferentiation is enhanced by certain small molecules, includ-
ing retinoic acid (56), oxytocin (37), ascorbic acid (49), and
nitric oxide donors (17, 33), but due to their low efficiencies,
these are highly disadvantageous for therapeutic applica-
tions. Exploitable new approaches are actively being sought,
and an effective strategy might be to bring inducible cell
defense mechanisms to bear on the process of differentiation.
Mitochondrial biogenesis is regulated both by energy-
dependent signals and by localized reactive oxygen species
(ROS) production; both induce the transcriptional program
to increase mitochondrial mass, particularly in aerobic organs
such as the heart (18). The exact mitochondrial sensing
and signaling of impending changes in cellular energetics
during differentiation are poorly understood functionally,
temporally, and spatially (32). This information gap creates a
barrier for effective therapeutic use of various exogenous
cardiac progenitor cells (CPCs) to improve bioenergetics and
myocardial regeneration (5). For any pluripotent cell to adopt
an adult contractile cardiomyocyte phenotype, however, it
embodies a vast expansion of bioenergetic capacity during
differentiation.
One critical myocardial defense for energy metabolism
involves the inducible heme oxygenase-1 (HO-1; Hmox1)
system, the rate-limiting step in heme catalysis (25). The
enzyme eliminates heme, a potent pro-oxidant, and releases
iron, biliverdin, and carbon monoxide (CO), which have
important signaling and cytoprotective properties (54). Be-
yond heme clearance, the HO-1/CO system links mitochon-
drial redox status to the redox-active transcription factors,
nuclear respiratory factor-1 (NRF-1) and nuclear factor
erythroid 2-related factor 2 (Nfe2l2), which promote mito-
chondrial biogenesis (38, 48). Cardiac HO-1/CO induction
stimulates gene expression for Tfam and opposes mito-
chondrial drug cardiotoxicity (47).
If modulation of mitochondrial biogenesis through the
HO-1/CO system (4, 30) could be used to program ES cells
onto a differentiation pathway, it may be possible to accel-
erate cardiomyocyte lineage development. It has been known
that mitochondrial biogenesis is activated during the cell
cycle (23), but no role has been identified for HO-1/CO. In
this study, we demonstrate a critical regulatory step in ES cell
embarkation to cardiomyocytes that is controlled by the HO-
1/CO system through the mitochondrial biogenesis pathway.
Mechanistically, HO-1/CO operates at a checkpoint involv-
ing CO, mitochondrial ROS, and mtDNA replication that are
amenable to pharmacological intervention.
Results
CO-dependent loss of ES cell pluripotency
Undifferentiated mouse ES cells (E14) showed high ex-
pression of the pluripotency markers, transcription factor
SOX-2 (Sox2) and POU domain, class 5, transcription factor
1 (Oct4). Stem cell differentiation into embryoid bodies
(EBs) demonstrated a gradual loss of expression of these
genes apparent by 72 h (Fig. 1A, B). After application of CO-
releasing molecule (CORM)-2 at 25 lM (58), loss of plu-
ripotent gene expression was accelerated by 72 h and there
was dose-dependent repression of Sox2 and Oct4 by CORM-
2 (Fig. 1C, D). These effects in E14 cells were confirmed in
two other ES lines, mouse D3 and human HS-MEL-1 cells
(Fig. 1E, F).
To compare changes in pluripotency with mitochondrial
mass, we tracked nuclear Oct4 localization, HO-1 protein
induction, and mitochondrial mass. HO-1 protein was in-
duced in control EBs by day 7 (data not shown), while
CORM-2 treatment enhanced early HO-1 expression (by day
3) compared with controls (Fig. 2A). For Oct4 and mito-
chondrial mass (using MitoTracker green), we performed
immunofluorescence microscopy under control and CORM-
2-treated conditions (Fig. 2B[a–c]). During early differenti-
ation (day 3), nuclear Oct4 was present in all conditions, but
less nuclear staining (puncta) was observed in EBs treated
with CORM-2 (Fig. 2B[d–f]). Oct4 nuclear staining was
strongly attenuated at days 7–9. To evaluate HO-1, the en-
zymewas silenced and the effect of CORM-2was determined
on Oct4 expression. HO-1 silencing delayed the loss of Oct4
(Fig. 2B[g–i]), an effect only marginally reversed by CORM-
2 (Fig. 2B[j–l]). Images of untreated control cells are shown in
Figure 2B(m–o).
Innovation
The importance of heme oxygenase-1/carbonmonoxide
(HO-1/CO) in embryonic stem (ES) cell differentiation is
shown by the requirement for the enzyme and for redox
activation of mitochondrial biogenesis mediated by
physiological levels of CO. HO-1/CO induction leads to
mitochondrial reactive oxygen species generation and
upregulation of proteins required for mitochondrial DNA
replication before ES cell differentiation (2). The linkage
to mitochondrial biogenesis is shown by loss-of-function
experiments that interrupt the program and block the
effectiveness of the CO messenger gas on differentia-
tion. These findings put the HO-1/CO system and heme
catabolism at a regulatory checkpoint in ES cell dif-
ferentiation and cardiomyocyte maturation. Prior work
suggesting that stem cell use, perhaps including marrow-
derived cells, may contribute to repair of infarcts in excess
of cell engraftment may indicate paracrine effects (26, 36,
45). Thus, agents that activate HO-1 in ES cell differen-
tiation in vitro or in vivo may be expected to contribute to
regenerative cell therapy in patients with advanced heart
disease.
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To distinguish serum-driven cardiac differentiation, E14
cells were cultured in hanging drops and the emerging EBs
placed individually into tissue culture plates, and cardiac
development was monitored by examination of rhythmically
contracting focal areas. Spontaneously beating focal areas
within individual differentiated EBs were observed from day
7, with >55% of EBs containing beating areas by the end of
the experiment (Fig. 2C). In CORM-2 (25 lM)-treated EBs,
beating areas reached 80% by day 13. Contrastingly, HO-1
silencing almost completely abrogated the appearance of
beating areas and was not improved by CORM-2 treatment
(Fig. 2C).
ES cell differentiation
Mouse ES cells were able to develop into structural and
functional cardiomyocytes. In the hanging drop stage, EB
aggregates in control media or in media plus CORM-2 had a
similar morphological appearance and size for the first 2 days
(not shown), indicating no basic perturbations of EB forma-
tion by the compound. For cardiac differentiation, changes
in nuclear expression of critical transcription factors, ho-
meobox protein Nkx-2.5 (Nkx2.5) and transcription factor
Gata4 (GATA4), were monitored by immunochemical
staining (Fig. 3A, B). Nkx2.5 and GATA4 nuclear staining
was more widespread in CORM-2- than in inactivated
CORM (iCORM)-treated EBs (Fig. 3A, B[a, b], respective-
ly). HO-1-silenced cells showed rare nuclei that stained for
Nkx2.5 and GATA4 even after CORM-2 (Fig. 3A, B[c, d],
respectively). Immunoblot analysis indicated increases in EB
nuclear Nkx2.5, GATA4, Mef2c, and in particular heart- and
neural crest derivatives-expressed protein 1 (Hand1) proteins
and their inhibition with shHO-1 (Fig. 3C). These transcrip-
tion factors are characteristically activated in well-differentiated
cardiomyocytes, and CORM-2 was especially effective for
Hand1, a noncanonical E-box transcription factor required for
cardiac morphogenesis. Immunoblot analysis also documented
the extent to which CORM-2 stimulated EB maturation into
cardiomyocytes. The responses included increased expression
of cardiac MHC6, MLC-2a, MLC-2v, and troponin I (cTnI)
proteins consistent with the contractile myocyte (Fig. 3D, upper
panel). CORM-2 also progressively increased cardiac structural
marker levels for a-actinin, connexin 43 (Cxn43), and brain
natriuretic peptide (BNP) (Fig. 3C, lower panel).
Mitochondrial expansion promotes cardiac
differentiation
Mitochondrial expansion is a key step in differentiation that
involves mtDNA transcription, replication, protein synthesis,
and activation of oxidative phosphorylation (10). Since HO-1/
CO regulates mitochondrial proliferation (48), we considered
that mitochondrial pathway activation might induce ES cell
differentiation. Using mitochondrial content monitoring by
FIG. 1. Oct4 and Sox2 mRNA expression levels in ES cells. (A, B) The mRNA levels for Oct3/4 and Sox2 pluripotency
genes in E14 cells in the absence of LIF decline between 0 and 72 h where 0 is control value. Loss of Oct 3/4 and Sox2
mRNA expression is accelerated in E14 cells exposed to CORM-2 (25 lM) after LIF withdrawal, but not iCORM. (C, D)
E14 cells demonstrate CORM-2 concentration-dependent loss of Oct3/4 and Sox2 mRNA expression at 72 h after dose
escalation. (E, F) CORM-2 accelerates loss of Oct4 and Sox2 mRNA in human MEL-1 and mouse mD3 ES cells (at 72 h
after 25lM CORM-2). Values are mean –SD of 3–4 independent experiments. Asterisks indicate significant differences
from control (Concentration or Time 0 by ANOVA; p < 0.05). ANOVA, analysis of variance; CORM-2, CO-releasing
molecule; ES, embryonic stem; iCORM, inactivated CORM; LIF, leukemia inhibitory factor; SD, standard deviation. To see
this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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fluorescence microscopy and fluorescence staining of citrate
synthase (CS), we found that CORM-2 (25lM) significantly
augmented EB mitochondrial mass (Fig. 4A) and CORM-2
treatment significantly increased mtDNA content in differenti-
ating EBs by mtDNA measurements (Fig. 4B). Since mtDNA
replication depends on nuclear NRF-1, PGC-1a coactivator, and
importedmitochondrial factors such as Polc andTfam (43), these
four transcripts were checked in EBs (Fig. 4C–F) and increased
mRNA levels were found for NRF-1 and PGC-1a by day 3 and
for Polc and Tfam by day 7, coinciding with the peak change in
mtDNA content (Fig. 4B). This also increased mitochondrial
transcriptional activity as shown by enhanced expression of
mtDNA-encoded subunit II of complex IV (cytochrome c oxi-
dase subunit 2 [COII]; Fig. 4G).
FIG. 2. HO-1 induction and loss of pluripotency in ES cells. (A) Control ES cells show increases in HO-1 mRNA levels
after exposure to CORM-2 (25lM), while iCORM has no effect. Cells transfected with Sh-HO-1 show 70–80% suppression
of HO-1 mRNA relative to control. Sh-vector does not affect HO-1 expression and the cells behave like controls. Data
analyzed by T test and presented as mean – SD of three separate experiments. (*p < 0.05 iCORM compared with CORM-2).
(B) E14 cells were stained for mitochondria and loss of OCT3/4 on days 3, 7, and 9. Mitochondria are stained with
MitoTracker (green), nuclei with DAPI (blue), and anti-OCT4 (red). (a–c) E14 cells treated with iCORM. Nuclear Oct4
appears pink. As the nucleus loses OCT4, mitochondrial proliferation is initiated. (d–f) E14 cells treated with CORM-2
(25 lM) display complete loss of nuclear OCT4 by day 7. (g–i) E14 cells after transfection with ShHO-1 show delayed
nuclear OCT4 loss. (j–l) E14 cells transfected with Sh-HO-1 and treated with CORM-2 show persistence of nuclear OCT4
at day 7. (m–o) Images of untreated control cells for comparison. Images acquired at 400·. (C) E14 cells cultured in
hanging drops for 2 days were plated onto gelatin-coated microtiter plates and treated at days 2, 5, and 7 with iCORM or
CORM-2 (25lM). Adherent EBs were monitored daily by inverted microscopy for spontaneous beating. Results are
percentage of beating EBs and represent mean – SD of five determinations. Control cells began beating by day 7. CORM-2
significantly increased the number of EB beating foci at days 7–13. Cells transduced with Sh-HO-1 showed few beating foci
and could not be rescued by CORM-2. (*p < 0.05 HO-1-silenced CORM-2 vs. CORM-2; **p < 0.05 WT CORM-2 vs.
iCORM on the same days). DAPI, 4¢,6-diamidino-2-phenylindole; EBs, embryoid bodies; HO-1/CO, heme oxygenase-1/
carbon monoxide; Oct/3/4, POU domain, class 5, transcription factor 1; WT, wild-type.
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Maturation of ES cells via redox signals
The role of mitochondrial ROS production as a maturation
signal was evaluated using transfection with mitochondrial-
targeted catalase (mCAT). With immunofluorescence for
sarcomeric a-actinin, we demonstrated a characteristic pat-
tern of banded continuous filaments in differentiating cells
that became more pronounced in CORM-2-treated cells
(Fig. 5A[a, c]). This supported the ability of ES cells to
generate cardiomyocyte structures and their augmentation by
CORM-2. EB cell differentiation was impaired by mCAT
transfection as indicated by poorly defined cardiac-specific a-
actinin filament staining (Fig. 5A[b, d]). The a-actinin fluo-
rescence signal increased significantly after CORM-2, and
mCAT reduced both the basal and CORM-2 effects (Fig. 5B,
C). This implicated mitochondrial redox signals in the car-
diac differentiation of ES cells (7, 11), and this mechanism
was further explored using the mitochondrial-targeted anti-
oxidant, mito-ubiquinone (MitoQ). The emergence of beat-
ing foci was quantified as above through day 13 in wild-type
FIG. 3. HO-1 activation drives E14 cell differentiation into beating cardiac cells. (A) Cardiac GATA4 (red) locali-
zation to nuclei stained with DAPI (blue). GATA4-positive nuclei are pink. (a) Control cells treated with iCORM, (b)
Control cells treated with CORM-2 (25 lM), (c) Sh-HO-1-transfected cells, (d) Sh-HO-1-transfected cells treated with
CORM-2. Nuclear accumulation of GATA4 is inhibited by Sh-HO-1 in iCORM and CORM-2-treated cells. Images
acquired at 200·. (B) Cardiac Nkx2.5 transcription factor expression and localization by immunofluorescence staining in
control and HO-1-silenced EBs (day 13). E14 cells were differentiated in the absence or presence of CORM-2. Nkx2.5 (red)
localization to nucleus is pink; nuclei stained with DAPI (blue). (a) Control cells plus iCORM, (b) Controls plus CORM-2
(25 lM), (c) ShHO-1-transfected cells, (d) Sh-HO-1-transfected cells treated with CORM-2. Nuclear localization is enriched
in cells treated with CORM-2. Images acquired at 200·. (C) Histograms of cardiac lineage nuclear proteins, Nkx2.5,
GATA4, Mef2c, and Hand1, relative to Lamin B loading control. Lineage marker expression is enhanced by CORM-2
(25 lM) and inhibited by Sh-HO-1. Gel shows a representative immunoblot for Hand1 versus Lamin B. (D) Upper panel,
Western blots for cardiac MHC6, MLC-2a, MLC-2v, and cTnI proteins after EB differentiation into cardiac lineage (day
13). Lower panel, immunoblot analysis showing CORM-2 enhancement of the expression of the structural cardiac proteins,
a-actinin, Cxn43, and BNP, at day 13 compared with day 0. Stripped blots were stained for b-actin as the loading control.
(E) Histogram quantification of (D). Values are mean – SD of three independent experiments (*p< 0.05). Hand1, heart- and
neural crest derivatives-expressed protein 1; Gata4, transcription factor Gata4; MLC2a, myosin regulatory light chain 2,
atrial isoform; Nkx2.5, homeobox protein Nkx-2.5.
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and mCAT-transfected EBs plus MitoQ with or without
CORM-2. Both MitoQ and mCAT transduction signifi-
cantly reduced the percentage of beating EBs and in concert
they greatly inhibited the CORM-2 effect (Fig. 5C). These
data together support that changes in mitochondrial re-
dox state induced by CORM-2 are necessary for EB differ-
entiation.
Tfam deficiency and ES cell differentiation
The transition from noncontractile ES cells into actively
beating cardiomyocytes requires an efficient metabolic and
electromechanical infrastructure (12, 35). Moreover, Tfam is
indispensable to mtDNA transcription and to the packaging
and stabilization of mtDNA during mitochondrial biogenesis
(2, 13). To determine if mitochondrial biogenesis is required
for ES cell differentiation, we used Tfam ablation (Fig. 6A).
In Tfam-/- cells, HO-1 gene upregulation by CORM-2 was
still weakly present (Fig. 6B), but differentiation into beating
cardiomyocytes was blocked as was the CORM-2 effect on it
(Fig. 6C). The impact of loss of Tfam on differentiation
was indicated by low a-actinin, MLC-2a, and cTnI protein
levels compared with controls even after CORM-2 treatment
(Fig. 6D). Additional evaluation of mitochondrial function
and expression of mitochondrial ETC complex and assembly
factors in Tfam-/- ES cells showed that NADH dehydroge-
nase I alpha subcomplex 1 of complex I (Ndufa1), as well as
complex I assembly factor 4 (Ndufaf4) were downregulated
FIG. 4. Mitochondrial biogenesis promotes cardiac differentiation in EBs. (A) Mitochondrial density in differenti-
ating EBs imaged at D13 using CS immunofluorescence (green). Nuclei stained blue with DAPI. (a) Control cells plus
iCORM, (b) Control cells plus CORM-2 (25lM), (c) ShHO-1-transfected cells, (d) ShHO-1-transfected cells plus CORM-2.
Mitochondrial density is most pronounced in CORM-2-treated cells, while ShHO-1-transfected cells show lowest mito-
chondrial density. Lower histogram is quantification of fluorescence intensity. Images acquired at 200·. (B) Changes
in mtDNA copy number during spontaneous and CORM-2-induced differentiation in murine EBs. (C–E) Mitochondrial gene
expression and EB cell differentiation. During differentiation, mRNA levels for upstream mtDNA regulators (NRF-1 and
PGC-1a) and downstream mtDNA transcription/replication regulators (Polc and Tfam) increase (F). Gene expression nor-
malized to 18S and expressed as fold change compared with day 0. (G) Mitochondrial COII gene expression by qPCR. Data
are fold changes compared with day 0. Significant differences between iCORM and CORM-2 treated cells (*p< 0.05). Values
are mean–SD of three independent experiments. COII, cytochrome c oxidase subunit 2; CS, citrate synthase; mtDNA,
mitochondrial DNA; NRF-1, nuclear respiratory factor-1; PGC-1a, peroxisome proliferator-activated receptor gamma
coactivator 1-alpha; Polc, DNA polymerase subunit gamma-1; qPCR, quantitative real-time RT-PCR; Tfam, mitochondrial
transcription factor A.
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(Fig. 6E).We also found depletion of complex IV protein COI
and COII expression (Fig. 6E), confirming the functional ef-
fectiveness of Tfam ablation. The effects shown in Figure 6D
and E are quantified in Figure 6F.
The loss of mitochondrial biogenesis as predicted also
blocked ES cell differentiation andmaturation into functional
cardiomyocytes. Tfam-/- ES cells had low mtDNA content,
which was restorable by Tfam transfection (Fig. 7A). Tfam
deficiency also reprogrammed the ES cell metabolically for
glycolysis as reflected by upregulation of pyruvate dehydroge-
nase kinase isozyme 1, mitochondrial (Pdk1), and hexokinase 2
(HK2). In contrast, the loss of Tfam decreased cardiolipin
synthase (Crls) and carnitineO-palmitoyltransferase 1 (Cpt1)
expression (Fig. 7B). CORM-2 was ineffective in preventing
these effects as in Figure 7B (negative data not shown).
Confirmation that Tfam deficiency lowered EB metabolic
activity was done by MTT assay (Fig. 7C), which showed
that a loss of Tfam decreased MTT reduction and was not
improved by CORM-2 treatment. The net energetic effect
was a lower average ATP content and a higher ADP/ATP
ratio revealing a relative energy insufficiency in differentia-
tion (Fig. 7D).
Maturation of the mitochondrial network
during cardiogenesis
The dependence of cardiac differentiation and maturation on
mitochondrial number, phenotype, and structural organization
hence depends on genes involved in mitochondrial network
formation (8). In tracking mRNA levels for selected genes in-
volved in network formation and maintenance through day 13
in wild-type (WT) and Tfam-deficient cells, we found greatly
increased fission (fragmentation) protein 1 (mitochondrial fis-
sion 1 protein [Fis1]) after loss of Tfam, while CORM-2, which
had no effect on Fis1 levels in WT cells, increased Fis1 in
Tfam-/- cells (Fig. 8A). The mRNA responses for Dynamin-1-
like protein (Dnm1l) were similar both after Tfam deletion and
after CORM-2 treatment (Fig. 8B). In contrast, mRNA levels
for the crista junction maturing mitofilin protein (MICOS
complex subunit Mic60 [Immt]) decreased significantly in
Tfam-/- cells and, after CORM-2, increased significantly only
in differentiatingWT control cells (Fig. 8C). Similarly, mRNA
levels for mitofusin 2 (Mfn2), an essential transmembrane
GTPase that mediates mitochondrial fusion, and optic atrophy
type 1 (dynamin-like 120 kDa protein, mitochondrial [Opa1])
FIG. 5. Cellular redox state and differentiation of mouse ES cells into cardiomyocytes. EBs were developed by
hanging drop and harvested at different times of cardiac differentiation. (A) For differentiation markers, day 13 EBs were
digested and single-cell suspensions subjected to immunofluorescence staining of cardiac myofibrils with cardiac anti-a-
sarcomeric actinin (green). Nuclei are stained blue (DAPI). (a) iCORM-treated cells, (b) CORM-2-treated cells (25lM), (c)
Cells transfected with mCAT on day 3 and collected at day 13, (d) Cells transfected with mCAT and then treated with
CORM-2 (25lM). CORM-2-treated cells exhibit a classical striated appearance of mature cardiomyocytes. Final magni-
fication 500·. (B) Histogram for quantification of a-sarcomeric actinin fluorescence intensity in (A). (C) ES cells were
differentiated and then transfected with mCAT or treated with MitoQ (0.3lM), then exposed to CORM-2 (25lM). The
number of beating foci was counted on day 13. Values are mean – SD of four experiments from independent batches of
cells. (*p< 0.05 > control; {p< 0.05 < control by ANOVA). mCAT, mitochondrial catalase; MitoQ, mito-ubiquinone.
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were downregulated in Tfam-/- cells and upregulated only
in WT controls by CORM-2 (Fig. 8D, E). The Immt and
Mfn2 protein levels paralleled the changes of their mRNA
levels (Fig. 8F). This pattern of changes in these four pro-
teins indicates that Tfam deficiency blocks mitochondrial
network formation and that CORM-2 can accelerate mito-
chondrial network formation only in mtDNA replication-
sufficient cells.
H9c2 cardiomyoblast differentiation
To confirm that HO-1/CO signaling is integral to cardiac
differentiation, we used adult myocardioblasts (H9c2 cells)
and checked their ability to differentiate morphologically
by shape elongation and multinucleation. HO-1 mRNA ex-
pression was induced in these cells by CORM-2 (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/ars), which also modulated morpho-
logical characteristics such as elongation and cell fusion,
as well as proliferation tracked by changes in cell cycle
marker, cyclin-dependent kinase 2 (CDK2), mRNA levels
(Supplementary Fig. S1A). In HO-1-silencing experiments,
myogenin and the myosin regulatory light chain 2 (Myl2)
contractile apparatus protein were upregulated by CORM-2
in an HO-1-dependent manner (Supplementary Fig. S1A).
The implication is that the HO-1/CO system promotes cell
cycle arrest in preparation for the synchronous expansion
of myogenic differentiation. H9c2 cell differentiation was
accompanied by mitochondrial network development and
maturation, especially after CORM-2 administration (Sup-
plementary Fig. S1B). Orderly emergence of the mitochon-
drial network tracked by Mfn2 staining indicated disruption
of cardiomyocyte differentiation steps by HO-1 silencing,
leaving behind a discontinuous mitochondrial network
FIG. 6. Disruption of differentiation in Tfam-deficient ES cells. (A, B) Tfam and HO-1 mRNA expression by qPCR
and Tfam protein by immunoblot in WT and Tfam-/- cell EBs at day 7. Asterisks indicate significant differences in iCORM
versus CORM-2, and crosses are WT versus Tfam-/- cells ( p< 0.05) by T-test. CORM-2 is ineffective in Tfam-/- cells.
Values are mean – SD of three independent experiments. (C) Tfam-deficient ES cells cannot differentiate into beating
cardiomyocytes and CORM-2 cannot rescue them. Differences between iCORM and CORM-2 treatment and WT and
Tfam-/- EBs are significant ( p < 0.05). N = 3–4 experiments per group. (D) Western analysis of a-actinin, MLC-2a, and cTnI
protein expression in Tfam-/- cells compared with WT cells (tubulin control). (E) Immunoblot analysis of mitochondrial
ETC member proteins, COI and COII, and assembly factors, Ndufa1 and Ndufaf4 (porin control). (F) Histogram for
quantification of protein in (D, E). Two-way ANOVA was used for data analysis. Values are mean – SD of n = 4 inde-
pendent batches of cells (*p < 0.05 WT iCORM vs. CORM-2; {p < 0.05 WT vs. Tfam-/-). ETC, electron transport complex.
To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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FIG. 7. Tfam depletion decreases mtDNA and alters ES cell metabolic phenotype. (A) Decrease in mtDNA copy
number as a result of Tfam deficiency is rescued by transfection of Tfam into Tfam-/- ES cells. (B) Metabolism-related
Pdk1, HK2, Crls, and Cpt1 mRNA expression. (C) Histogram for functional MTT reduction in WT control and Tfam-/-
cells at day 13. CORM-2 enhances the metabolic activity (MTT reduction) in EB controls, but had no effect on Tfam-/-
cells. (D) ADP/ATP ratio in Tfam-deficient and WT control cells treated with CORM-2. Values are mean – SD of n = 3
batches of cells (*p < 0.05 iCORM vs. CORM-2; {p < 0.05 WT vs. Tfam-/- by two-way ANOVA). Cpt1, carnitine O-
palmitoyltransferase 1; CRLS, cardiolipin synthase; HK2, hexokinase 2; Pdk1, pyruvate dehydrogenase kinase isozyme 1, mito-
chondrial. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
FIG. 8. EB mitochondrial network maturation during cardiac differentiation. (A, B) The expression of genes involved in
mitochondrial fission and membrane remodeling increases only in Tfam-/- cells (Dnm1l and Fis1). (C, D) Expression of genes
involved in mitochondrial fusion and cristae maturation (Immt and Mfn2) in control and Tfam-/- cells at day 13 of differentiation.
(E) OPA1 cristae protein increases with CORM-2 treatment only in WT cells. (F) Immt and Mfn2 protein expression in control
and Tfam-/- cells at day 13 of differentiation. Asterisks indicate iCORM versus CORM-2 (*p<0.05). Crosses ({) indicate
Tfam-/- compared with WT cells (p<0.05). Values are mean–SD of three independent experiments. Dnm1l, dynamin-1-like
protein; Fis1, mitochondrial fission 1 protein; Mfn2, mitofusin 2; Opa1, dynamin-like 120kDa protein, mitochondrial. To see this
illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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reminiscent of fusion impairment. Mitochondrial expansion
and network formation were accelerated by CORM-2 as
shown by increased expression of inner membrane, mitofilin
(Immt), and outer membrane, Mfn2, which was absent after
HO-1 silencing (Supplementary Fig. S1C).
To visualize the myocytes, we used sarcomeric a-actinin
immunofluorescence staining to locate increases in actin
filament assembly with clear sarcomere cross-striation and
increased cell size. This was more pronounced in CORM-2-
treated cells (Supplementary Fig. S2A). Early transduction
with sh-HO-1 blocked these responses, and a-actinin in those
cells appeared as unassembled or disarrayed filaments or
aggregates (Supplementary Fig. S2A).
CPCs in adult mouse heart
Because the cellular work strongly supported a regulatory
role for HO-1 induction, and specifically for endogenous CO
production in cardiomyocyte differentiation, we sought
in vivo evidence of relevance in mice. As CO also appeared to
be a key pharmacological mechanism of action of CORM-2,
which was unavailable in large enough quantities for in vivo
studies, we induced the HO-1/CO system in the mouse heart
using inhaled CO (47) and checked for evidence of CPC
expansion ex vivo (Supplementary Fig. S3). After 3 days of
intermittent CO breathing, the mouse hearts contained new
clusters of Sca1+ cells, consistent with expansion of the
progenitor cell population (Supplementary Fig. S3A–C). CO
also increased the cardiomyocyte lineage commitment as
indicated by increases in Nkx2.5 protein expression (Sup-
plementary Fig. S3D–F; p < 0.05).
Discussion
These studies demonstrate that the cell-protective HO-1/
CO system, which promotes energy homeostasis in the heart
and other tissues (40), also helps regulate the differentiation
of murine ES into functional cardiac cells. The data show
temporal and spatial connections between changes in HO-1
gain and loss of function and corresponding changes in
mitochondrial mass. In pluripotent cells, the expression of
cardiac-specific structural genes is preceded by mitochon-
drial biogenesis, and the emergence of the morphological
contractile phenotype is blocked by HO-1 silencing and
stimulated by a novel CO-releasing molecule. Moreover, the
HO-1/CO system promotes differentiation through mito-
chondrial ROS production, which is required in the ES cell
transition into the cardiac lineage. Mitochondrial-targeted
antioxidants prevent ES cell differentiation, while Tfam
knockdown blocks it even after CO. This means that mito-
chondrial proliferation and maturation are definitive mecha-
nisms to actually drive cardiomyocyte phenotype.
Studies on the role of the HO-1/CO system in cardiac
regeneration have proposed the facilitation of CPC mobili-
zation by improving their migration, proliferation, and/or
viability (19). Similarly, HO-1 induction in transplanted
mesenchymal stem cells (MSCs) augments their regenerative
potential in infarcted or ischemic myocardium. These salu-
tary effects are attributable, in part, to improved cell viability
or to a better balance between proangiogenic growth factor
production and proinflammatory cytokine production (50,
53), but data have so far been lacking on precise molecular
pathways and rates of MSC differentiation. Moreover, in-
duction of the mitochondrial signaling pathway through HO-
1 operates in connection with Akt/PKB (48), which has a
known role in the proliferation of cardiomyocytes derived
from human ES cells (28).
The differentiation of ES cells along the cardiac lineage
creates a characteristic gene expression profile that includes
the early expression of a network of mesodermal cardiac
transcription factors such as Nkx2.5, Gata4, and Mef2c,
which activate gene expression for structural proteins, MHC,
Mlc2v, and troponin I (3). In this study, the early upregulation
of the Nkx2.5 cardiac transcription factor and the repression
of OCT4, followed by increases in mitochondrial mass, were
greatly facilitated by CORM-2. HO-1 induction mirrored
loss of OCT4 and was linked to accelerated mitochondrial
network formation, thereby exposing the heme and energy
requirements of terminal differentiation. HO-1 silencing
markedly decreases nuclear Nkx2.5 and Gata4 expression
and localization in EB outgrowths, which delays and de-
creases the number of self-contracting foci. CORM-2 had no
ability to rescue the contractile phenotype in HO-1-silenced
cells, thereby indicating that HO-1/CO, in this setting, is
necessary for the development of contractile activity. Ex-
pansion of the mitochondrial population for terminal differ-
entiation in EBs was accompanied by increases in a-actinin,
MHC, Mlc2v, and troponin T proteins and was facilitated by
CO, further implicating HO-1/CO in regulation of cardio-
myogenesis.
The origin of cardiomyocytes from ES cells is well de-
scribed empirically, but a lack of complete lineage definitions
has made it difficult to devise interventions involving oxi-
dant/antioxidant balance (1, 21, 49). Accordingly, the influ-
ence of mitochondrial redox state on cardiomyogenesis is
known only insofar as what selected antioxidants inhibit, while
mitochondrial ROS facilitates cardiac differentiation (42). In
this study, we report that mitochondrial ROS production oc-
curring early in cardiomyocyte differentiation promotes and
enhances differentiation, while the CO molecule acting as a
lynchpin is driving expansion of the mitochondrial population.
ES cell transfection with mCAT prevented a-actinin upregu-
lation and the development of contractile function, while
augmentation of differentiation by CORM-2 was abrogated by
mCAT and mitoQ, thereby underscoring the importance of
sensing the mitochondrial redox state.
Although certain redox-active compounds at high levels,
such as ascorbate, tend to promote cardiac differentiation,
postcommitment the molecule has no additional effect (49).
The capacity of CO to induce mitochondrial biogenesis by
slowing the ETC and enhancing mitochondrial ROS leak rate
not only activates antioxidant response genes but certain
cardiac-specific genes as well (38, 47, 48). Our work supports
the operation of this mechanism because mitochondrial-
targeted antioxidants block the CORM-2 response and inhibit
cardiomyocyte maturation.
The mitochondrial actions of the HO-1/CO system pro-
vided our focal point because the differentiation steps for the
cardiac lineage eventually give rise to a compatible bioen-
ergetic state (10, 41). Typically, energy demand dynamically
regulates mitochondrial number and functional capacity in
the cardiomyocyte, and as the rate of respiration increases, so
does the cell’s mitochondrial density. Thus, key proteins that
facilitate and coordinate mtDNA transcription and replica-
tion, including NRF-1 and PGC-1a, tracked with Polc and
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Tfam early in differentiation and led to subsequent expres-
sion of mitochondrial-encoded proteins. This is reminiscent
of a conditioning effect on aerobic differentiation of cardio-
myocytes analogous to the transition from fetal to neonatal
life where cardiac metabolism switches away from glucose as
the preferred substrate for ATP generation (44, 46).
The dependence of undifferentiated ES cells on glycoly-
sis and the low respiration rates of such highly proliferative
cells are reflected by low mtDNA copy number and low
mitochondrial-encoded COII levels (44). In murine ES cells,
Tfam deficiency provided evidence of depressed mitochon-
drial function and reversion to glycolysis as demonstrated
by high HK2 and Pdk1 expression. By forcing reentry into
glycolysis, stem maintenance and differentiation are nega-
tively impacted, and retransfection of Tfam-/- cells with
Tfam vector improves mtDNA levels and allows return of
aerobic metabolism and differentiation. That mitochondrial
biogenesis per se influences cardiac differentiation implies
that the organelle directs the ES cell toward a phenotype
capable of maintaining an efficient energetic infrastructure
(8). Pluripotency regulators are known to influence energy
metabolism and the balance between glycolysis and oxida-
tive metabolism (10); hence, aerobic metabolism regulates
not only cell fate and self-renewal (8) but also the capacity for
differentiation.
Disruption of HO-1 interrupted mitochondrial network
organization and compromised the development of energetic
infrastructure accompanied by improper sarcomere forma-
tion, poor beating area assembly, and defective contractility.
Although CORM-2 was found to be quite potent in WT cells,
in the absence of HO-1, CORM-2 did not rescue differenti-
ation, implying that HO-1 is essential and that our pharma-
cological CO release profile did not fully capture the
physiological regulatory processes involving HO-1. These
processes would include the enzyme’s roles in heme turnover
and iron handling, which are topics for further investigation.
Several molecular prerequisites underlying the generation
of energetically competent cardiomyocytes have been iden-
tified in the transition of stem cells to heart cell progenitors.
For instance, two critical fusion-facilitating genes (Mfn2 and
Immt) were increased in differentiating ES cells, but mito-
chondrial fission proteins did not change. The former proteins
are required for crista junction maintenance and inner
membrane architecture, allowing contact sites to form on the
outer membrane. Thus, mitochondrial network fusion and
expansion in connection with respiratory capacity are able to
support a cardiac phenotype (10). Coordination of maturation
with mitochondrial biogenesis highlights the specificity
of mitochondrial to nuclear retrograde communication for
cardiomyogenesis and cardiac differentiation. Accordingly,
final differentiation occurs after the mitochondria are func-
tional, and interference with completion of biogenesis by
Tfam knockdown also interrupts differentiation and degrades
EB beating.
Similarly, in differentiated rat H9c2 embryonic cardio-
myoblasts, the HO-1/CO system has a key role in the ex-
pression of cardiac gene products and sarcomere structures in
a developmentally regulated manner. Both lines express
molecular cardiac markers and maintain the ability to dif-
ferentiate into multinucleated myotubes (38). In H9c2 cells,
CORM-2 upregulates the myogenin transcription factor,
which promotes muscle-specific target gene expression dur-
ing muscle differentiation and participates in cell cycle exit.
Contractile apparatus proteins such as Myl2 are upregulated
by myogenic differentiation, a hallmark of the differentiated
phenotype of mature myogenic cells. Myl2 mRNA expres-
sion is also enhanced by CORM-2 and prevented by HO-1
silencing. Thus, the HO-1/CO system in both cell lines drives
ES cell differentiation toward the functional cardiomyocyte
by a redox-dependent mechanism of activation of mito-
chondrial biogenesis.
Finally, the relevance of these cellular events is seen by
expansion of the pool of cardiac progenitors in the mouse
heart after brief exposures to CO by inhalation in vivo. The
level and duration of these exposures are insufficient to re-
cruit hypoxic mechanisms (48), but sufficient to increase the
number of Sca1 and Nkx2.5-expressing cells in the heart.
This finding implies significant biological potential for car-




All chemicals and reagents were purchased from Sigma or
Molecular Probes (Invitrogen,) unless otherwise indicated. A
water-soluble CO-releasing molecule, CORM-2, synthesized
and characterized at the University of Zurich (57, 58) was
used to produce endogenous levels of CO. This well-
characterized agent binds to B12 receptors and releases two
molecules of CO in *20min along with one of soluble
ReO4, which is nontoxic and is excreted in vivo. We dissi-
pated the prodrug in phosphate-buffered saline (PBS) for 1 h
before applying it to cells as iCORM. Dose ranging studies
were performed in murine ES and rat H9c2 cells to identify
CORM-2 concentrations that did not cause lactate dehy-
drogenase release or cell death from CO toxicity.
Cell culture
Mouse ES cells (E14-TG2a; American Type Culture
Collection, ATCC) were grown in gelatin-coated plastic tis-
sue culture flasks and maintained in Iscove’s modified Dul-
becco’s medium (Life Technologies; # 12440053) containing
15% newborn calf serum (Atlanta Biologicals), nonessential
amino acids, and nucleosides. To prevent differentiation, 2-
mercaptoethanol (100 lM) and leukemia inhibitory factor
(LIF 1000U/ml; EMD Millipore; #ESG1106) were added to
the media. To induce differentiation, a hanging drop method
was used (14).
On day 0, ES cells were cultivated without LIF in hanging
drops (30ll) to form EBs (*1000 cells per drop) for 2 days,
then held in suspension. On day 4, the EBs were indepen-
dently plated on gelatin-coated 96-well plates, single-culture
dishes, or slides and grown in differentiation mediumwithout
LIF. This consisted of Dulbecco’s modified Eagle’s medium
(DMEM), 15% fetal calf serum, 0.1mM mercaptoethanol,
and 1% nonessential amino acids. For CORM2, the drug was
prepared in differentiation medium (5–25 lM final concen-
trations) and was changed every 1–2 days. Rhythmically
beating aggregates in EB outgrowths were observed daily by
light microscopy to record morphology and number of
beating cardiomyocytes. The ADP/ATP ratio was determined
HO-1 AND CARDIAC PROGENITOR CELLS 355
using ApoSENSOR (# K255-200; BioVision, Inc.) with the
manufacturer’s instructions.
Two other ES cell lines were used in confirmatory stud-
ies, the mESC line, D3 (ATCC), and hESC line, MEL-1
(#SCC020; Chemicon). Feeder-free mES D3 cells were
cultured on Nunclon surface dishes. The MEL-1 line was
maintained on mitotically inactivated mouse embryonic fi-
broblasts in gelatin-coated culture dishes as recommended
by the supplier (Chemicon). All cells were maintained at
37Cwith5%CO2 inDMEM(Gibco), supplementedwith15%
heat-inactivated fetal bovine serum (FBS; Hyclone), GIBCO
reagents 0.5mM b-mercaptoethanol, 2mM l-glutamine,
0.1mM MEM nonessential amino acid, and 5000U/ml
penicillin/streptomycin, and for MEL-1 cells, insulin–trans-
ferrin–selenium (ITS # 41400-045; Life Technologies) is
added instead of LIF.
Cell transfection
Transfections were performed in six-well plates at 70–80%
confluence with mCAT vector or HuSH shRNA (pGFPCRS)
vector containing HO-1 oligonucleotide sequence for optimal
suppression of HO-1 (#TR30018; Origene), using FuGENE-
HD(#E2311;Promega).After24–48 h, the cellswere subjected
to drug selection at either 500lg/ml G418 (#10131035; Life
Technologies) or 4lg/ml puromycin (#A1113803; Life Tech-
nologies) to assess transfection stability. These procedures did
not result in measurable cell toxicity or cell death. Antibiotic-
resistant colonies were expanded and the transfected cells
harvested for EB formation or further measurements. To con-
firmmCAT expression or HO-1 knockdown, quantitative real-
time RT-PCR (qPCR) was used.
MTT assay
Active mitochondrial mass was determined by the reduc-
tion of yellow MTT (#11465007001; Sigma/Roche) to the
purple formazan by mitochondrial enzymes. ES cells plated
at 10,000 per well were analyzed by adding 10 ll of MTT
reagent to each well. After incubation in standard or differ-
entiation media at 37C for 4 h, MTT was removed and the
precipitate solubilized at room temperature. Absorbance was
determined at 540 nm by a microplate reader (Molecular
Devices). MTT reduction was defined as [100 · (absorbance
of treated cells) / (absorbance of control cells)].
CRE recombination
For Cre recombinase-stimulated deletion of loxP sites in
ES E14/Tfam/loxp derivative cells [generated in our lab-
oratory after (13)], *1 million cells were electroporated
with 50 lg pBS185 (Cre recombinase expression vector;
Life Technologies) using 225V and 950 lF or 230V and
500 lF parameters. Cells were replated on ES medium,
and 48 h after electroporation, stably transfected cells were
selected using G418 started at 300 lg/ml. Seven to nine
days later, colonies were counted (to determine the fre-
quency of G418R colonies), isolated in 96-well plates, and
expanded in 24-well dishes before freezing. G418 selec-
tion was maintained throughout the expansion. Fractions
of these clones were put on gelatin-coated plates and
tested functionally for loss of puromycin effect or used to
extract nucleic acids. A single ES cell clone carrying Tfam
deletion was replated for clonal expansion in fresh ES
medium containing 1000U/ml LIF. After expansion, the
cells were gradually differentiated as above. For rescue
experiment, cells were transfected with pLenti-Tfam
vector (#MR203015L2; Origene).
Rat H9c2 cells
Rat cardiomyoblast-derived H9c2 cells (ATCC CRL1446)
were grown in Dulbecco’s minimal essential medium con-
taining 10% FBS and 1% (v/v) antibiotic mixture at 37C in a
humidified atmosphere containing 5% CO2. Cells were in-
duced to differentiate toward the cardiac-like phenotype of
Menard et al. (29). Following decreases in growth factor
concentration, myoblasts rapidly become multinucleated
myotubes; therefore, subculturing was performed precon-
fluence to prevent spontaneous transdifferentiation into a
skeletal phenotype. Differentiation was induced by culturing
myoblasts in DMEM supplemented with 1% fetal calf serum.
CORM-2 (25lM) was added at days 1 and 3, and media
replaced every 2 days. H9c2 cardiomyoblasts were trans-
fected with mCAT vector (48) or Sh-HO-1 (Origene) using
FuGENE-HD (Roche). Cells transfected with pcDNA3 vec-
tor lacking the insert were the controls. Transfected cells
were differentiated as above.
RNA extraction
Total cellular RNA was extracted using the RNAqueous-
4PCR kit (Ambion) according to the manufacturer’s in-
structions. Samples were treated with DNase I (4U) for 2 h
at 37C, then inactivated with DNase. The RNA was re-
verse transcribed using the Reverse Transcription System
(Promega).
Real-time qPCR
cDNA was prepared with a high-capacity cDNA archive
kit (Applied Biosystems), according to the manufacturer’s
suggestions. Real-time qPCR primers for HO-1, NRF-1, Polc,
PGC-1a, Tfam, COII, Oct4, Sox2, CS, CRLS-1, Dnm1, Fis1,
Pdk1, HK2, CPt1, CDK2, MLC2 (Myl7) and MLC2v, myo-
genin, and 18S from Applied Biosystems were used with the
manufacturer’s protocol. All reactions were conducted on
StepOnePlus for 40 cycles. The results were analyzed using
the 2-DDCt method after being normalized to the level of 18S
in each sample.
mtDNA copy number
Total cellular DNA was extracted using the Sigma DNA
isolation kit. mtDNA copy number was quantified with real-
time PCR on the StepOnePlus Sequence Detector System
(AB Applied Biosystems). Primers were designed for cyto-
chrome b (Cyt b) with ABI Probe Design software (Applied
Biosystem) and amplifications performed on 10 ng total
mtDNA using PCR primers (cyt b-s and cyt b-as). One
copy of linearized pGEMT-cyt b vector (47) was used
for standard mtDNA quantification. The cyt b probe, 5¢
FAM-ttcctccacgaaacaggatcaaa-TAMRA 3¢, contained FAM
(6-carboxyfluorescein) at the 5¢ end as a fluorescent reporter
dye and, at the 3¢ end, the TAMRA (6-carboxy-tetramethylr-
hodamine) as a quencher dye selected from a highly con-
served region of mouse cyt b gene. Serial dilutions of 105–10
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copies of standard cyt b plasmid were prepared for a standard
curve. Samples were tested for mtDNA at 1:100 and 1:1000
dilutions. Samples were analyzed in triplicate, and mtDNA
copy number/ng DNA determined relative to the standards
known mtDNA copies per dilution.
Immunoblot analysis
Cell lysates were prepared from cell preparations (H9c2 or
E14 cells) and equal amounts of protein (20–30lg) separated
by sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis. Membranes were incubated with validated polyclonal
rabbit antibodies against COI, COII (#PA5-26688, # A-6404;
Life Technologies), myosin regulatory light chain 2, atrial
isoform (sc-34488), MLC2v (sc-34490), Mfn2 (sc-50331),
Immt (sc-79636), Mef2c (sc-365862), Hand1(sc-374296),
Cxn43 (sc-6560), LaminB (sc-374015), BNP (sc-271185), a-
-actinin(sc-15335), cTnI(sc-20642), porin (sc-390996),MHC6
(sc-168676), and OPA1 (sc-30573), all from Santa Cruz.
Secondary antibody was 1:5000 horseradish peroxidase-
conjugated goat anti-rabbit or anti-mouse immunoglobulin G
(Santa Cruz), as appropriate. Blots were developed with ECL,
quantified on digitized images in the mid-dynamic range, and
expressed relative to Lamin B, tubulin, b-actin, or porin.
Immunohistochemical imaging
Live cells on single slide chambers were incubated in
media containing 250 nM MitoTracker green (Molecular
Probes, Invitrogen). After 30min, this was followed by three
washes in media and fixation with 4% formaldehyde in 1·
PBS. Fixed cells were permeabilized with 0.2% Triton X-100
and immunostained by first digesting EBs with 3mg/ml
collagenase II (Gibco) for 15min at 37C. Cells were re-
suspended in differentiation media, plated onto gelatin-
coated single-chamber slides, and incubated overnight at
37C+ 5% CO2. ES cells were fixed in 2% formaldehyde
(Sigma) for 1 h, permeabilized for 30min in 1% (v/v) Triton
X-100, placed in blocking solution for 30min, and incubated
with antibody to CS (1:100; Molecular Probes), OCT3/4
(1:100; Santa Cruz), sacomeric a-actinin (Abcam), Gata 4,
Mfn2 (Santa Cruz), or Nxk2.5 (Cell Signaling) in PBS con-
taining 1% bovine serum albumin for 2 h at room tempera-
ture. After three washes, the cells were incubated with Alexa
Fluor secondary antibodies, followed by a nuclear probe
(4¢,6-diamidino-2-phenylindole; Invitrogen).
Confocal and fluorescence imaging
Fluorescent images were obtained with a Laser Scanning
Microscope 510 (Carl Zeiss Microimaging) and analyzed
using a Zeiss Laser Scanning Microscope Image Browser or
MetaMorph software (Universal Imaging Corporation). ES
cells were visualized on a Hamamatsu Digital Camera
C4742-95. Image data were collected using NIS-element 3.1
software (Nikon). Negative controls were used to determine
exposure times and prevent false positives.
Mouse studies
Mouse exposures were preapproved by the Duke IACUC.
Authentic CO gas was administered to 10- to 12-week-old
male B57L6 mice ( Jackson) in special plastic chambers at
200 ppm CO in air for 1 h to increase the carboxyhemoglobin
level to *20% without tissue hypoxia (22). Mice received
1 h of CO per day or room air for three consecutive days and
the hearts harvested at day 4. The hearts were fixed in 10%
formalin, paraffin embedded, and sectioned. For immuno-
fluorescence techniques, the sections were costained with
Sca1 (Abcam; # Ab51317) and CS (Cell Signaling; #14309)
or Nkx2.5 (Cell Signaling; #8792) and CS. The positive
cells in ventricles and atria were counted and expressed as a
percentage of number of nuclei per field (10 random fields
per slide and five slides per group) using NIS element 3.2
software.
Statistics
Grouped data are expressed as mean – standard deviation.
Each time point analysis contained at least three samples
from three to four experiments per group. Differences be-
tween iCORM and CORM-2 were determined by T test,
while time-dependent comparisons were made by two-way
analysis of variance, followed by Tukey’s post-test analysis
performed using Sigma Stat and Sigma Plot software (Sy-
stat Software, Inc.). p < 0.05 was considered significant,
and the statistical tests identified in the figure legends as
appropriate.
Acknowledgments
The authors thank Martha Salinas, Lynn Tatro, and Eli
Colman for technical assistance. This work was supported by
NHLBI: P01HL108801 04.
Author Contributions
H.B.S.: Conception and design, collection and assembly of
data, data analysis and interpretation, manuscript writing, and
final approval of manuscript. C.A.P.: Conception and design,
assembly of data, data analysis and interpretation, manuscript
writing, final approval of manuscript, and financial support.
F.Z.: Conception and design, provision of study material, data
analysis and interpretation, and final approval of manuscript.
Author Disclosure Statement
No competing financial interests exist.
References
1. Akazawa H and Komuro I. Roles of cardiac transcription
factors in cardiac hypertrophy. Circ Res 92: 1079–1088, 2003.
2. Alam TI, Kanki T, Muta T, Ukaji K, Abe Y, Nakayama H,
Takio K, Hamasaki N, and Kang D. Human mitochondrial
DNA is packaged with TFAM. Nucleic Acids Res 31: 1640–
1645, 2003.
3. Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodg-
son DM, Yamada S, Puceat M, Niederlander N, Alekseev
AE, Zingman LV, and Terzic A. Cardiopoietic program-
ming of embryonic stem cells for tumor-free heart repair. J
Exp Med 204: 405–420, 2007.
4. Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV,
and Wobus AM. Differentiation of pluripotent embryonic
stem cells into cardiomyocytes. Circ Res 91: 189–201, 2002.
5. Bolli R, Chugh AR, D’Amario D, Loughran JH, Stoddard
MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T,
Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi
NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, and
HO-1 AND CARDIAC PROGENITOR CELLS 357
Anversa P. Cardiac stem cells in patients with ischaemic
cardiomyopathy (SCIPIO): initial results of a randomised
phase 1 trial. Lancet 378: 1847–1857, 2011.
6. Bonawitz ND, Clayton DA, and Shadel GS. Initiation and
beyond: multiple functions of the human mitochondrial
transcription machinery. Mol Cell 24: 813–825, 2006.
7. Buggisch M, Ateghang B, Ruhe C, Strobel C, Lange S,
Wartenberg M, and Sauer H. Stimulation of ES-cell-
derived cardiomyogenesis and neonatal cardiac cell pro-
liferation by reactive oxygen species and NADPH oxidase.
J Cell Sci 120: 885–894, 2007.
8. Chen CT, Shih YR, Kuo TK, Lee OK, and Wei YH. Co-
ordinated changes of mitochondrial biogenesis and antioxi-
dant enzymes during osteogenic differentiation of human
mesenchymal stem cells. Stem Cells 26: 960–968, 2008.
9. Cho YM, Kwon S, Pak YK, Seol HW, Choi YM, Park Do J,
Park KS, and Lee HK. Dynamic changes in mitochondrial
biogenesis and antioxidant enzymes during the spontaneous
differentiation of human embryonic stem cells. Biochem
Biophys Res Commun 348: 1472–1478, 2006.
10. Chung S, Dzeja PP, Faustino RS, Perez-Terzic C, Behfar A,
and Terzic A. Mitochondrial oxidative metabolism is re-
quired for the cardiac differentiation of stem cells. Nat Clin
Pract Cardiovasc Med 4 Suppl 1: S60–S67, 2007.
11. Crespo FL, Sobrado VR, Gomez L, Cervera AM, and
McCreath KJ. Mitochondrial reactive oxygen species me-
diate cardiomyocyte formation from embryonic stem cells
in high glucose. Stem Cells 28: 1132–1142, 2010.
12. Dzeja PP and Terzic A. Phosphotransfer networks and
cellular energetics. J Exp Biol 206: 2039–2047, 2003.
13. Ekstrand MI, Falkenberg M, Rantanen A, Park CB, Gaspari
M, Hultenby K, Rustin P, Gustafsson CM, and Larsson NG.
Mitochondrial transcription factor A regulates mtDNA copy
number in mammals. Hum Mol Genet 13: 935–944, 2004.
14. Gissel C, Doss MX, Hippler-Altenburg R, Hescheler J, and
Sachinidis A. Generation and characterization of cardio-
myocytes under serum-free conditions. Methods Mol Biol
330: 191–219, 2006.
15. Hance N, Ekstrand MI, and Trifunovic A. Mitochondrial
DNA polymerase gamma is essential for mammalian em-
bryogenesis. Hum Mol Genet 14: 1775–1783, 2005.
16. Jeong-Yu S and Clayton DA. Regulation and function of the
mitochondrial genome. J Inherit Metab Dis 19: 443–451, 1996.
17. Kanno S, Kim PK, Sallam K, Lei J, Billiar TR, and Shears
LL, 2nd. Nitric oxide facilitates cardiomyogenesis in
mouse embryonic stem cells. Proc Natl Acad Sci U S A
101: 12277–12281, 2004.
18. Karamanlidis G, Bautista-Hernandez V, Fynn-Thompson F,
Del Nido P, and Tian R. Impaired mitochondrial biogenesis
precedes heart failure in right ventricular hypertrophy in
congenital heart disease. Circ Heart Fail 4: 707–713, 2011.
19. Lakkisto P, Kyto V, Forsten H, Siren JM, Segersvard H,
Voipio-Pulkki LM, Laine M, Pulkki K, and Tikkanen I.
Heme oxygenase-1 and carbon monoxide promote neo-
vascularization after myocardial infarction by modulating
the expression of HIF-1alpha, SDF-1alpha and VEGF-B.
Eur J Pharmacol 635: 156–164, 2010.
20. Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P,
Lewandoski M, Barsh GS, and Clayton DA. Mitochondrial
transcription factor A is necessary for mtDNA maintenance
and embryogenesis in mice. Nat Genet 18: 231–236, 1998.
21. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y,
Woodard S, Lin LZ, Cai CL, Lu MM, Reth M, Platoshyn
O, Yuan JX, Evans S, and Chien KR. Postnatal isl1+ car-
dioblasts enter fully differentiated cardiomyocyte lineages.
Nature 433: 647–653, 2005.
22. Leary SC, Battersby BJ, Hansford RG, and Moyes CD.
Interactions between bioenergetics and mitochondrial bio-
genesis. Biochim Biophys Acta 1365: 522–530, 1998.
23. Lee S, Kim S, Sun X, Lee JH, and Cho H. Cell cycle-
dependent mitochondrial biogenesis and dynamics in
mammalian cells. Biochem Biophys Res Commun 2007.
24. Liu T and O’Rourke B. Enhancing mitochondrial Ca2+
uptake in myocytes from failing hearts restores energy
supply and demand matching. Circ Res 103: 279–288,
2008.
25. Maines MD. Heme oxygenase: function, multiplicity, reg-
ulatory mechanisms, and clinical applications. FASEB J 2:
2557–2568, 1988.
26. Malecki M, Sabo C, Putzer E, Stampe C, Foorohar A, Quach
C, Beauchaine M, Tombokan X, and Anderson M. Recruit-
ment and retention of human autologous CD34+ CD117+
CD133+ bone marrow stem cells to infarcted myocardium
followed by directed vasculogenesis: novel strategy for car-
diac regeneration. Mol Cell Ther 1: pii 4, 2013.
27. Mandal S, Lindgren AG, Srivastava AS, Clark AT, and
Banerjee U. Mitochondrial function controls proliferation
and early differentiation potential of embryonic stem cells.
Stem Cells 29: 486–495, 2011.
28. McDevitt TC, Laflamme MA, and Murry CE. Proliferation
of cardiomyocytes derived from human embryonic stem
cells is mediated via the IGF/PI 3-kinase/Akt signaling
pathway. J Mol Cell Cardiol 39: 865–873, 2005.
29. Menard C, Pupier S, Mornet D, Kitzmann M, Nargeot J,
and Lory P. Modulation of L-type calcium channel ex-
pression during retinoic acid-induced differentiation of
H9C2 cardiac cells. J Biol Chem 274: 29063–29070, 1999.
30. Miller-Hance WC, LaCorbiere M, Fuller SJ, Evans SM,
Lyons G, Schmidt C, Robbins J, and Chien KR. In vitro
chamber specification during embryonic stem cell cardio-
genesis. Expression of the ventricular myosin light chain-2
gene is independent of heart tube formation. J Biol Chem
268: 25244–25252, 1993.
31. Montaigne D, Hurt C, and Neviere R. Mitochondria death/
survival signaling pathways in cardiotoxicity induced by
anthracyclines and anticancer-targeted therapies. Biochem
Res Int 2012: 951539, 2012.
32. Moyes CD, Battersby BJ, and Leary SC. Regulation of
muscle mitochondrial design. J Exp Biol 201: 299–307, 1998.
33. Mujoo K, Sharin VG, Bryan NS, Krumenacker JS, Sloan C,
Parveen S, Nikonoff LE, Kots AY, and Murad F. Role of
nitric oxide signaling components in differentiation of
embryonic stem cells into myocardial cells. Proc Natl Acad
Sci U S A 105: 18924–18929, 2008.
34. Murry CE, Field LJ, and Menasche P. Cell-based cardiac
repair: reflections at the 10-year point. Circulation 112:
3174–3183, 2005.
35. Naya FJ, Black BL, Wu H, Bassel-Duby R, Richardson JA,
Hill JA, and Olson EN. Mitochondrial deficiency and car-
diac sudden death in mice lacking the MEF2A transcription
factor. Nat Med 8: 1303–1309, 2002.
36. Oldroyd KG, Berry C, and Bartunek J. Myocardial repair
and regeneration: bone marrow or cardiac stem cells? Mol
Ther 20: 1102–1105, 2012.
37. Paquin J, Danalache BA, Jankowski M, McCann SM, and
Gutkowska J. Oxytocin induces differentiation of P19
embryonic stem cells to cardiomyocytes. Proc Natl Acad
Sci U S A 99: 9550–9555, 2002.
358 SULIMAN ET AL.
38. Piantadosi CA, Carraway MS, Babiker A, and Suliman HB.
Heme oxygenase-1 regulates cardiac mitochondrial bio-
genesis via Nrf2-mediated transcriptional control of nuclear
respiratory factor-1. Circ Res 103: 1232–1240, 2008.
39. Rivolta MN and Holley MC. Asymmetric segregation of
mitochondria and mortalin correlates with the multi-lineage
potential of inner ear sensory cell progenitors in vitro.
Brain Res Dev Brain Res 133: 49–56, 2002.
40. Ryter SW, Alam J, and Choi AM. Heme oxygenase-1/
carbon monoxide: from basic science to therapeutic appli-
cations. Physiol Rev 86: 583–650, 2006.
41. San Martin N, Cervera AM, Cordova C, Covarello D,
McCreath KJ, and Galvez BG. Mitochondria determine the
differentiation potential of cardiac mesoangioblasts. Stem
Cells 29: 1064–1074, 2011.
42. Sauer H, Rahimi G, Hescheler J, and Wartenberg M. Role
of reactive oxygen species and phosphatidylinositol 3-
kinase in cardiomyocyte differentiation of embryonic stem
cells. FEBS Lett 476: 218–223, 2000.
43. Scarpulla RC. Transcriptional paradigms in mammalian
mitochondrial biogenesis and function. Physiol Rev 88:
611–638, 2008.
44. Spitkovsky D, Sasse P, Kolossov E, Bottinger C, Fleisch-
mann BK, Hescheler J, and Wiesner RJ. Activity of com-
plex III of the mitochondrial electron transport chain is
essential for early heart muscle cell differentiation. FASEB
J 18: 1300–1302, 2004.
45. Sreejit P and Verma RS. Natural ECM as biomaterial for
scaffold based cardiac regeneration using adult bone mar-
row derived stem cells. Stem Cell Rev 9: 158–171, 2013.
46. St. John JC, Ramalho-Santos J, Gray HL, Petrosko P, Rawe
VY, Navara CS, Simerly CR, and Schatten GP. The expression
of mitochondrial DNA transcription factors during early car-
diomyocyte in vitro differentiation from human embryonic
stem cells. Cloning Stem Cells 7: 141–153, 2005.
47. SulimanHB,CarrawayMS,AliAS,ReynoldsCM,Welty-Wolf
KE, and Piantadosi CA. The CO/HO system reverses inhibition
of mitochondrial biogenesis and prevents murine doxorubicin
cardiomyopathy. J Clin Invest 117: 3730–3741, 2007.
48. Suliman HB, Carraway MS, Tatro LG, and Piantadosi CA.
A new activating role for CO in cardiac mitochondrial
biogenesis. J Cell Sci 120: 299–308, 2007.
49. Takahashi T, Lord B, Schulze PC, Fryer RM, Sarang SS,
Gullans SR, and Lee RT. Ascorbic acid enhances differ-
entiation of embryonic stem cells into cardiac myocytes.
Circulation 107: 1912–1916, 2003.
50. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, and Phillips
MI. Improved graft mesenchymal stem cell survival in is-
chemic heart with a hypoxia-regulated heme oxygenase-1
vector. J Am Coll Cardiol 46: 1339–1350, 2005.
51. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA,
Swiergiel JJ, Marshall VS, and Jones JM. Embryonic stem
cell lines derived from human blastocysts. Science 282:
1145–1147, 1998.
52. Tilemann L, Ishikawa K, Weber T, and Hajjar RJ. Gene
therapy for heart failure. Circ Res 110: 777–793, 2012.
53. Tsubokawa T, Yagi K, Nakanishi C, Zuka M, Nohara A, Ino
H, Fujino N, Konno T, Kawashiri MA, Ishibashi-Ueda H,
Nagaya N, and Yamagishi M. Impact of anti-apoptotic and
anti-oxidative effects of bone marrow mesenchymal stem
cells with transient overexpression of heme oxygenase-1 on
myocardial ischemia. Am J Physiol Heart Circ Physiol 298:
H1320–H1329, 2010.
54. Wagener FA, Volk HD, Willis D, Abraham NG, Soares
MP, Adema GJ, and Figdor CG. Different faces of the
heme-heme oxygenase system in inflammation. Pharmacol
Rev 55: 551–571, 2003.
55. Williams RS. Mitochondrial gene expression in mammalian
striated muscle. Evidence that variation in gene dosage is the
major regulatory event. J BiolChem 261: 12390–12394, 1986.
56. Wobus AM, Kaomei G, Shan J, Wellner MC, Rohwedel J, Ji
G, Fleischmann B, Katus HA, Hescheler J, and Franz WM.
Retinoic acid accelerates embryonic stem cell-derived car-
diac differentiation and enhances development of ventricular
cardiomyocytes. J Mol Cell Cardiol 29: 1525–1539, 1997.
57. Zobi F and Blacque O. Reactivity of 17 e- complex
[Re(II)Br4(CO)2]2- with bridging aromatic ligands. Char-
acterization and CO-releasing properties. Dalton Trans 40:
4994–5001, 2011.
58. Zobi F, Blacque O, Jacobs RA, Schaub MC, and Bogda-
nova AY. 17 e(-) rhenium dicarbonyl CO-releasing mole-
cules on a cobalamin scaffold for biological application.
Dalton Trans 41: 370–378, 2012.
Address correspondence to:
Dr. Claude A. Piantadosi




Date of first submission to ARS Central, March 24, 2015;
date of final revised submission, October 19, 2015; date of
acceptance, November 6, 2015.
Abbreviations Used
ANOVA¼ analysis of variance
BNP¼ brain natriuretic peptide
CDK2¼ cyclin-dependent kinase 2
COII¼ cytochrome c oxidase subunit 2
CORM-2¼CO-releasing molecule
CPC¼ cardiac progenitor cell
Cpt1¼ carnitine O-palmitoyltransferase 1
CRLS-1¼ cardiolipin synthase
CS¼ citrate synthase
cTnI¼ cardiac troponin I
Cxn43¼ connexin 43
Cyt b¼ cytochrome b
DAPI¼ 4¢,6-diamidino-2-phenylindole
DMEM¼Dulbecco’s modified Eagle’s medium
Dnm1l¼ dynamin-1-like protein
ES¼ embryonic stem
ETC¼ electron transport complex
FBS¼ fetal bovine serum
Fis1¼mitochondrial fission 1 protein
Gata4¼ transcription factor Gata4
Hand1¼ heart- and neural crest derivatives-expressed
protein 1
HK2¼ hexokinase 2
HO-1/CO¼ heme oxygenase-1/carbon monoxide
iCORM¼ inactivated CORM
Immt¼MICOS complex subunit Mic60
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MLC2a¼myosin regulatory light chain 2, atrial
isoform
mtDNA¼mitochondrial DNA
Myl2¼myosin regulatory light chain 2
Nkx2.5¼ homeobox protein Nkx-2.5
NRF-1¼ nuclear respiratory factor-1
Nrf2¼ nuclear factor erythroid 2-related factor 2
NRFs¼ nuclear respiratory factors
Oct/3/4 ¼ POU domain, class 5, transcription factor 1
Opa1 ¼ dynamin-like 120 kDa protein, mitochondrial
PBS ¼ phosphate-buffered saline
Pdk1 ¼ pyruvate dehydrogenase kinase isozyme 1,
mitochondrial
PGC-1a ¼ peroxisome proliferator-activated receptor
gamma coactivator 1-alpha
Polc ¼ DNA polymerase subunit gamma-1
qPCR ¼ quantitative real-time RT-PCR
ROS ¼ reactive oxygen species
SD ¼ standard deviation
Sox2 ¼ transcription factor SOX-2
Tfam ¼ mitochondrial transcription factor A
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